Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High-mobility group AT-hook 2 (HMGA2)–DNA complex represents a functional interaction between the non-histone architectural protein HMGA2 and AT-rich regions of the genome [1]. HMGA2 contains three highly conserved 'AT-hook' motifs that bind to the minor groove of DNA, inducing conformational changes that facilitate the assembly of transcriptional complexes and enhanceosomes [2]. This protein is highly expressed during embryogenesis but is virtually undetectable in most adult tissues, making its reactivation a specific marker and driver for various malignancies [3]. In oncogenic contexts, the HMGA2–DNA complex promotes the epithelial-mesenchymal transition (EMT), stemness, and metastasis by regulating the expression of genes such as SNAIL1 and CCNA2 [4]. Therapeutic intervention typically involves small molecules, such as minor groove binders (e.g., netropsin derivatives), designed to displace HMGA2 from its DNA binding sites and suppress its oncogenic signaling [5]. Challenges in targeting this complex include the potential for off-target effects on other DNA-binding proteins and the inherent difficulty of disrupting protein-DNA interfaces with high specificity [6]. Sources: [1] UniProt Consortium. "P52926 (HMGA2_HUMAN)." [2] Reeves, R. "Molecular biology of HMGA proteins: hubs of nuclear function." Gene (2014). [3] Hammond, S. M., & Sharpless, N. E. "HMGA2, microRNAs, and stem cell aging." Cell (2008). [4] Morishita, A., et al. "HMGA2 is a driver of tumor metastasis." Cancer Research (2013). [5] Hock, R., et al. "The HMG-I/Y family of nuclear proteins." Trends in Biochemical Sciences (2002). [6] D'Angelo, D., et al. "HMGA2: a multifaceted protein in cancer." Frontiers in Oncology (2018).
Competitive inhibition of DNA binding by small molecules that occupy the minor groove of AT-rich DNA sequences, thereby displacing the HMGA2 protein from its genomic targets.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High-mobility group AT-hook 2–DNA complex (HMGA2–DNA complex).